177Lu- labeled MOv18 as compared to 131I- or 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts

Nuclear Medicine and Biology

Volumn 36, Issue 7, 2009, Pages 759-770

  Zacchetti, Alberto ^a   Coliva, Angela ^a   Luison, Elena ^a   Seregni, Ettore ^a   Bombardieri, Emilio ^a   Giussani, Augusto ^b   Figini, Mariangela ^a   Canevari, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Monoclonal antibody MOv18; Ovarian cancer; Radioimmunotherapy; Radiometals, Folate Receptor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 4 ISOTHIACYANOTOBENZYL1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; FOLATE RECEPTOR; IODINE 131; ISOPROTEIN; ISOTHIOCYANIC ACID DERIVATIVE; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MOV18; MONOCLONAL ANTIBODY MOV18 I 131; MONOCLONAL ANTIBODY MOV18 LU 177; MONOCLONAL ANTIBODY MOV18 Y 90; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; CANCER SIZE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG UPTAKE; FEMALE; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; OVARY CANCER; RADIOIMMUNOTHERAPY; THERAPY EFFECT; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; LUTETIUM; MAXIMUM TOLERATED DOSE; MICE; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECEPTORS, CELL SURFACE; TIME FACTORS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN; YTTRIUM RADIOISOTOPES;

EID: 69249203546     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.05.004     Document Type: Article

References (39)

1. von G.V., Daly B., Gibbons H., Hutchins J., and Green A. Indicators of survival duration in ovarian cancer and implications for aggressiveness of care. Cancer 112 (2008) 2221-2227
2. Ayhan A., Gultekin M., Celik N.Y., Dursun P., Taskiran C., Aksan G., et al. Occult metastasis in early ovarian cancers: risk factors and associated prognosis. Am J Obstet Gynecol 196 (2007) 81-86
3. Epithelial ovarian cancer. In: Berek J.S., and Hacker N.F. (Eds). Practical gynecological oncology (1994), Williams and Wilkins, Baltimore 327
4. Yap T.A., Carden C.P., and Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9 (2009) 167-181
5. Luborsky J.L., Barua A., Shatavi S.V., Kebede T., Abramowicz J., and Rotmensch J. Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol 54 (2005) 55-62
6. Nicodemus C.F., and Berek J.S. Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther 5 (2005) 87-96
7. Coliva A., Seregni E., Figini M., Zacchetti A., Fontanelli R., Raspagliesi F., et al. Nuclear medicine in the treatment of ovarian cancer. In: Bombardieri E., Buscombe J.R., Lucignani G., and Schober O. (Eds). Advances in nuclear oncology: diagnosis and therapy (2007), Informa Healthcare, London 383-396
8. Oei A.L., Sweep F.C., Thomas C.M., Boerman O.C., and Massuger L.F. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer. review. Int J Oncol 32 (2008) 1145-1157
9. Koppe M.J., Postema E.J., Aarts F., Oyen W.J., Bleichrodt R.P., and Boerman O.C. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev 24 (2005) 539-567
10. Knogler K., Grunberg J., Zimmermann K., Cohrs S., Honer M., Ametamey S., et al. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin Cancer Res 13 (2007) 603-611
11. Lewington V. Development of 131I-tositumomab. Semin Oncol 32 (2005) S50-S56
12. Buchsbaum D.J., Langmuir V.K., and Wessels B.W. Experimental radioimmunotherapy. Med Phys 20 (1993) 551-567
13. Almqvist Y., Steffen A.C., Tolmachev V., Divgi C.R., and Sundin A. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer. Nucl Med Biol 33 (2006) 991-998
14. Crippa F., Buraggi G.L., Di Re E., Gasparini M., Seregni E., Canevari S., et al. Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. Eur J Cancer 27 (1991) 724-729
15. Crippa F., Bolis G., Seregni E., Gavoni N., Bombardieri E., Scarfone G., et al. Single dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 131I-MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 31A (1995) 686-690
16. Weitman S.D., Weinberg A.G., Coney L.R., Zurawski Jr. V.R., Jennings D.S., and Kamen B.A. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 52 (1992) 6708-6711
17. Bueno R., Appasani K., Mercer H., Lester S., and Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 121 (2001) 225-233
18. Zhu D., and Pauli B.U. Generation of monoclonal antibodies directed against organ- specific endothelial cell surface determinants. J Histochem Cytochem 39 (1991) 1137-1142
19. Andersson H., Lindegren S., Back T., Jacobsson L., Leser G., and Horvath G. Biokinetics of the monoclonal antibodies MOv 18, OV 185 and OV 197 labelled with 125I according to the m-MeATE method or the Iodogen method in nude mice with ovarian cancer xenografts. Acta Oncol 38 (1999) 323-328
20. Andersson H., Palm S., Lindegren S., Back T., Jacobsson L., Leser G., et al. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. Anticancer Res 21 (2001) 409-412
21. Gadina M., Canevari S., Ripamonti M., Mariani M., and Colnaghi M.I. Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18. Nucl Med Biol 18 (1991) 403-408
22. Coliva A., Zacchetti A., Luison E., Tomassetti A., Bongarzone I., Seregni E., et al. . 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother 54 (2005) 1200-1213
23. Figini M., Martin F., Ferri R., Luison E., Ripamonti E., Zacchetti A., et al. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunol Immunother 58 (2009) 531-546
24. Committee on Cancer Research (UKCCCR), United Kingdom. Guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77 (1998) 1-10
25. 2000 Report of the AVMA panel on euthanasia. J Am Vet Med Assoc 218 (2001) 669-696
26. International Union of Pure and Applied Chemistry CoCT. The Gold Book. 2nd ed. (1997), Blackwell Scientific Publications, Oxford
27. Foltz C.J., and Ullman-Cullere M. Guidelines for assessing the health and condition of mice. Lab Animal 28 (1999) 28-32
28. Behr T.M., Sgouros G., Vougiokas V., Memtsoudis S., Gratz S., Schmidberger H., et al. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer 76 (1998) 738-748
29. Stein R., Govindan S.V., Chen S., Reed L., Richel H., Griffiths G.L., et al. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. J Nucl Med 42 (2001) 967-974
30. Berndorff D., Borkowski S., Sieger S., Rother A., Friebe M., Viti F., et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 11 (2005) 7053s-7063s
31. Beck R., Seidl C., Pfost B., Morgenstern A., Bruchertseifer F., Baum H., et al. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice. Cancer Sci 98 (2007) 1215-1222
32. Behr T.M., Sharkey R.M., Sgouros G., Blumenthal R.D., Dunn R.M., Kolbert K., et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 80 (1997) 2591-2610
33. Casalini P., Luison E., Menard S., Colnaghi M.I., Paganelli G., and Canevari S. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J Nucl Med 38 (1997) 1378-1381
34. Mantovani L.T., Miotti S., Menard S., Canevari S., Raspagliesi F., Bottini C., et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer 30A (1994) 363-369
35. Casalini P., Mezzanzanica D., Canevari S., Della Torre G., Miotti S., Colnaghi M.I., et al. Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: analysis of cell binding and internalization. Int J Cancer 48 (1991) 284-290
36. Brouwers A.H., van Eerd J.E., Frielink C., Oosterwijk E., Oyen W.J., Corstens F.H., et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 45 (2004) 327-337
37. Siegel J.A. Quantitative Bremsstrahlung SPECT imaging: attenuation-corrected activity determination. J Nucl Med 35 (1994) 1213-1216
38. O'Donoghue J.A., Bardies M., and Wheldon T.E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36 (1995) 1902-1909
39. Coney L.R., Mezzanzanica D., Sanborn D., Casalini P., Colnaghi M.I., and Zurawski Jr. V.R. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res 54 (1994) 2448-2455